Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Valero

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
Journal of Molecular Endocrinology|February 22, 2015
Metabolic differences between white and brown fat from fasting rabbits at physiological temperatureZ López-Ibarra, J Modrego, M Valero-Muñoz, et al.
Rheumatology (Oxford, England)|February 12, 2008
Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patientsP García de la Peña-Lefebvre, S Rodríguez Rubio, M Valero Expósito, et al.
Revista Espanola De Medicina Nuclear E Imagen Molecular|August 20, 2013
[Validation of segmentation techniques for positron emission tomography using ex-vivo images of oncological surgical specimens]E Prieto, J M Martí-Climent, M Gómez-Fernández, et al.
Plos Pathogens|November 5, 2019
The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon responseLeon Louis Seifert, Clara Si, Debjani Saha, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2020
A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CL<sup>pro</sup> inhibitor PF-00835231 as a potential new treatment for COVID-19Maren de Vries, Adil S Mohamed, Rachel A Prescott, et al.
Journal of Virology|February 24, 2021
A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL<sup>pro</sup> inhibitor PF-00835231 as a potential new treatment for COVID-19Maren de Vries, Adil S Mohamed, Rachel A Prescott, et al.
Biorxiv : the Preprint Server for Biology|October 14, 2022
A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8Bruno A Rodriguez-Rodriguez, Grace O Ciabattoni, Ralf Duerr, et al.
Nature Communications|May 25, 2023
A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8Bruno A Rodriguez-Rodriguez, Grace O Ciabattoni, Ralf Duerr, et al.
Journal of Clinical Pathology|September 14, 2021
Laboratory interpretative comments and guidance: clinical and operative outcomes on moderate to severe hyponatraemia patient managementBlanca Montero-San-Martín, Paloma Oliver, Pilar Fernandez-Calle, et al.
Research Square|August 3, 2021
Gut microbiome dysbiosis during COVID-19 is associated with increased risk for bacteremia and microbial translocationMericien Venzon, Lucie Bernard-Raichon, Jon Klein, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Journal of Molecular Endocrinology|February 22, 2015
Metabolic differences between white and brown fat from fasting rabbits at physiological temperatureZ López-Ibarra, J Modrego, M Valero-Muñoz, et al.
Rheumatology (Oxford, England)|February 12, 2008
Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patientsP García de la Peña-Lefebvre, S Rodríguez Rubio, M Valero Expósito, et al.
Revista Espanola De Medicina Nuclear E Imagen Molecular|August 20, 2013
[Validation of segmentation techniques for positron emission tomography using ex-vivo images of oncological surgical specimens]E Prieto, J M Martí-Climent, M Gómez-Fernández, et al.
Plos Pathogens|November 5, 2019
The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon responseLeon Louis Seifert, Clara Si, Debjani Saha, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2020
A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CL<sup>pro</sup> inhibitor PF-00835231 as a potential new treatment for COVID-19Maren de Vries, Adil S Mohamed, Rachel A Prescott, et al.
Journal of Virology|February 24, 2021
A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL<sup>pro</sup> inhibitor PF-00835231 as a potential new treatment for COVID-19Maren de Vries, Adil S Mohamed, Rachel A Prescott, et al.
Biorxiv : the Preprint Server for Biology|October 14, 2022
A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8Bruno A Rodriguez-Rodriguez, Grace O Ciabattoni, Ralf Duerr, et al.
Nature Communications|May 25, 2023
A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8Bruno A Rodriguez-Rodriguez, Grace O Ciabattoni, Ralf Duerr, et al.
Journal of Clinical Pathology|September 14, 2021
Laboratory interpretative comments and guidance: clinical and operative outcomes on moderate to severe hyponatraemia patient managementBlanca Montero-San-Martín, Paloma Oliver, Pilar Fernandez-Calle, et al.
Research Square|August 3, 2021
Gut microbiome dysbiosis during COVID-19 is associated with increased risk for bacteremia and microbial translocationMericien Venzon, Lucie Bernard-Raichon, Jon Klein, et al.
Pageof 14